-
1
-
-
0015370976
-
The effect of castration and estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
Huggins C, Hodges CV. The effect of castration and estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40.
-
(1972)
CA Cancer J Clin
, vol.22
, pp. 232-240
-
-
Huggins, C.1
Hodges, C.V.2
-
2
-
-
74049152290
-
Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer
-
Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
-
(2010)
J Natl Cancer Inst
, vol.102
, pp. 39-46
-
-
Keating, N.L.1
O'Malley, A.J.2
Freedland, S.J.3
Smith, M.R.4
-
3
-
-
18644367900
-
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer
-
Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002;60(suppl 1):7-11.
-
(2002)
Urology
, vol.60
, Issue.SUPPL. 1
, pp. 7-11
-
-
Meng, M.V.1
Grossfeld, G.D.2
Sadetsky, N.3
Mehta, S.S.4
Lubeck, D.P.5
Carroll, P.R.6
-
4
-
-
77149172555
-
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology
-
Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833-40.
-
(2010)
Circulation
, vol.121
, pp. 833-840
-
-
Levine, G.N.1
D'Amico, A.V.2
Berger, P.3
-
5
-
-
52049122207
-
Cognitive effects of hormone therapy in men with prostate cancer: A review
-
Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008;113:1097-106.
-
(2008)
Cancer
, vol.113
, pp. 1097-1106
-
-
Nelson, C.J.1
Lee, J.S.2
Gamboa, M.C.3
Roth, A.J.4
-
6
-
-
0036062598
-
Long-term effects of androgen deprivation therapy in prostate cancer patients
-
Basaria S, Lieb J 2nd, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779-86.
-
(2002)
Clin Endocrinol (Oxf)
, vol.56
, pp. 779-786
-
-
Basaria, S.1
Lieb II, J.2
Tang, A.M.3
-
7
-
-
1842739187
-
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer
-
Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004;63:742-5.
-
(2004)
Urology
, vol.63
, pp. 742-745
-
-
Smith, M.R.1
-
8
-
-
0036173823
-
Changes in body composition during androgen deprivation therapy for prostate cancer
-
Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endo Metab 2002;87:599-603.
-
(2002)
J Clin Endo Metab
, vol.87
, pp. 599-603
-
-
Smith, M.R.1
Finkelstein, J.S.2
McGovern, F.J.3
-
9
-
-
0034847215
-
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer
-
Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endo Metab 2001;86:4261-7.
-
(2001)
J Clin Endo Metab
, vol.86
, pp. 4261-4267
-
-
Smith, J.C.1
Bennett, S.2
Evans, L.M.3
-
10
-
-
43049102727
-
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome
-
Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008;112:2188-94.
-
(2008)
Cancer
, vol.112
, pp. 2188-2194
-
-
Smith, M.R.1
Lee, H.2
McGovern, F.3
-
11
-
-
33646029746
-
Insulin sensitivity during combined androgen blockade for prostate cancer
-
Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-8.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 1305-1308
-
-
Smith, M.R.1
Lee, H.2
Nathan, D.M.3
-
12
-
-
70249149328
-
Impact of androgen deprivation therapy on cardiovascular disease and diabetes
-
Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452-8.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3452-3458
-
-
Alibhai, S.M.1
Duong-Hua, M.2
Sutradhar, R.3
-
13
-
-
33749058933
-
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
-
Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4448-4456
-
-
Keating, N.L.1
O'Malley, A.J.2
Smith, M.R.3
-
14
-
-
37349025015
-
Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer
-
Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 2007;70:1104-8.
-
(2007)
Urology
, vol.70
, pp. 1104-1108
-
-
Lage, M.J.1
Barber, B.L.2
Markus, R.A.3
-
15
-
-
0037326906
-
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia
-
Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195-201.
-
(2003)
Clin Sci (Lond)
, vol.104
, pp. 195-201
-
-
Dockery, F.1
Bulpitt, C.J.2
Agarwal, S.3
Donaldson, M.4
Rajkumar, C.5
-
16
-
-
34047174603
-
Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer
-
Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer. Arch Intern Med 2007;167:612-13.
-
(2007)
Arch Intern Med
, vol.167
, pp. 612-613
-
-
Basaria, S.1
Muller, D.C.2
Carducci, M.A.3
Egan, J.4
Dobs, A.S.5
-
17
-
-
0029062567
-
Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia
-
Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995;154:100-4.
-
(1995)
J Urol
, vol.154
, pp. 100-104
-
-
Eri, L.M.1
Urdal, P.2
Bechensteen, A.G.3
-
18
-
-
42949158874
-
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: Interim analysis of a multicenter phase iii study
-
Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase iii study. J Clin Oncol 2008;26:1824-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1824-1829
-
-
Smith, M.R.1
Malkowicz, S.B.2
Chu, F.3
-
19
-
-
34648828214
-
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
-
Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500.
-
(2007)
Cancer
, vol.110
, pp. 1493-1500
-
-
Saigal, C.S.1
Gore, J.L.2
Krupski, T.L.3
Hanley, J.4
Schonlau, M.5
Litwin, M.S.6
-
20
-
-
35548937873
-
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
-
Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 1516-1524
-
-
Tsai, H.K.1
D'Amico, A.V.2
Sadetsky, N.3
Chen, M.H.4
Carroll, P.R.5
-
21
-
-
34347271955
-
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
-
D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2420-2425
-
-
D'Amico, A.V.1
Denham, J.W.2
Crook, J.3
-
22
-
-
38349164176
-
Androgen suppression and radiation vs. radiation alone for prostate cancer: A randomized trial
-
D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-95.
-
(2008)
JAMA
, vol.299
, pp. 289-295
-
-
D'Amico, A.V.1
Chen, M.H.2
Renshaw, A.A.3
Loffredo, M.4
Kantoff, P.W.5
-
23
-
-
33646360629
-
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (eortc) trial 30891
-
Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (eortc) trial 30891. J Clin Oncol 2006;24:1868-76.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1868-1876
-
-
Studer, U.E.1
Whelan, P.2
Albrecht, W.3
-
24
-
-
44449088357
-
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of rtog 92-02
-
Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of rtog 92-02. Eur Urol 2008;54:816-23.
-
(2008)
Eur Urol
, vol.54
, pp. 816-823
-
-
Efstathiou, J.A.1
Bae, K.2
Shipley, W.U.3
-
25
-
-
39149085396
-
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of rtog 8610
-
Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of rtog 8610. J Clin Oncol 2008;26:585-91.
-
(2008)
J Clin Oncol
, vol.26
, pp. 585-591
-
-
Roach III, M.1
Bae, K.2
Speight, J.3
-
26
-
-
67149125847
-
Duration of androgen suppression in the treatment of prostate cancer
-
Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27.
-
(2009)
N Engl J Med
, vol.360
, pp. 2516-2527
-
-
Bolla, M.1
de Reijke, T.M.2
Van Tienhoven, G.3
-
27
-
-
58149337570
-
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85-31
-
Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: rtog 85-31. J Clin Oncol 2009;27:92-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 92-99
-
-
Efstathiou, J.A.1
Bae, K.2
Shipley, W.U.3
-
28
-
-
0036968877
-
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: A randomized controlled trial
-
Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90:427-32.
-
(2002)
BJU Int
, vol.90
, pp. 427-432
-
-
Green, H.J.1
Pakenham, K.I.2
Headley, B.C.3
-
29
-
-
0141954181
-
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer
-
Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 2003;170:1808-11.
-
(2003)
J Urol
, vol.170
, pp. 1808-1811
-
-
Cherrier, M.M.1
Rose, A.L.2
Higano, C.3
-
30
-
-
0141887365
-
Androgen deprivation and cognition in prostate cancer
-
Salminen E, Portin R, Korpela J, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 2003;89:971-6.
-
(2003)
Br J Cancer
, vol.89
, pp. 971-976
-
-
Salminen, E.1
Portin, R.2
Korpela, J.3
-
31
-
-
9344241426
-
Associations between serum testosterone fall and cognitive function in prostate cancer patients
-
Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004;10:7575-82.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 7575-7582
-
-
Salminen, E.K.1
Portin, R.I.2
Koskinen, A.3
Helenius, H.4
Nurmi, M.5
-
32
-
-
15744370022
-
Estradiol and cognition during androgen deprivation in men with prostate carcinoma
-
Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005;103:1381-7.
-
(2005)
Cancer
, vol.103
, pp. 1381-1387
-
-
Salminen, E.K.1
Portin, R.I.2
Koskinen, A.I.3
Helenius, H.Y.4
Nurmi, M.J.5
-
33
-
-
3042600342
-
One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men
-
Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004;29:1071-81.
-
(2004)
Psychoneuroendocrinology
, vol.29
, pp. 1071-1081
-
-
Almeida, O.P.1
Waterreus, A.2
Spry, N.3
Flicker, L.4
Martins, R.N.5
-
34
-
-
2542534543
-
Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial
-
Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004;93:975-9.
-
(2004)
BJU Int
, vol.93
, pp. 975-979
-
-
Green, H.J.1
Pakenham, K.I.2
Headley, B.C.3
-
36
-
-
21744456444
-
Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study
-
Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 2005;96:48-53.
-
(2005)
BJU Int
, vol.96
, pp. 48-53
-
-
Jenkins, V.A.1
Bloomfield, D.J.2
Shilling, V.M.3
Edginton, T.L.4
-
37
-
-
29144474501
-
Testosterone loss and estradiol administration modify memory in men
-
Beer TM, Bland LB, Bussiere JR, et al. Testosterone loss and estradiol administration modify memory in men. J Urol 2006;175:130-5.
-
(2006)
J Urol
, vol.175
, pp. 130-135
-
-
Beer, T.M.1
Bland, L.B.2
Bussiere, J.R.3
-
38
-
-
33750505645
-
Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer
-
Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006;176:2443-7.
-
(2006)
J Urol
, vol.176
, pp. 2443-2447
-
-
Joly, F.1
Alibhai, S.M.2
Galica, J.3
-
39
-
-
67349254217
-
Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer
-
Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 2009;18:237-47.
-
(2009)
Psychooncology
, vol.18
, pp. 237-247
-
-
Cherrier, M.M.1
Aubin, S.2
Higano, C.S.3
-
40
-
-
57649114702
-
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer
-
D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 2008;113:3290-7.
-
(2008)
Cancer
, vol.113
, pp. 3290-3297
-
-
D'Amico, A.V.1
Chen, M.H.2
Renshaw, A.A.3
Loffredo, M.4
Kantoff, P.W.5
-
41
-
-
54349117353
-
Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada
-
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, [Available online at, cited June 17, 2010]
-
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2008;32(suppl 1):S1-210. [Available online at: www.diabetes.ca/files/cpg2008/cpg-2008.pdf; cited June 17, 2010]
-
(2008)
Can J Diabetes
, vol.32
, Issue.SUPPL. 1
-
-
-
42
-
-
33750729609
-
Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review
-
Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006;60:201-15.
-
(2006)
Crit Rev Oncol Hematol
, vol.60
, pp. 201-215
-
-
Alibhai, S.M.1
Gogov, S.2
Allibhai, Z.3
-
43
-
-
34248169161
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
-
Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596-605.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1596-1605
-
-
Loblaw, D.A.1
Virgo, K.S.2
Nam, R.3
-
44
-
-
0025240079
-
Organizational effects of early gonadal secretions on sexual differentiation in spatial memory
-
Williams CL, Barnett AM, Meck WH. Organizational effects of early gonadal secretions on sexual differentiation in spatial memory. Behav Neurosci 1990;104:84-97.
-
(1990)
Behav Neurosci
, vol.104
, pp. 84-97
-
-
Williams, C.L.1
Barnett, A.M.2
Meck, W.H.3
-
45
-
-
0028929304
-
Gonadal hormone levels and spatial learning performance in the Morris water maze in male and female meadow voles, Microtus pennsylvanicus
-
Galea LA, Kavaliers M, Ossenkopp KP, Hampson E. Gonadal hormone levels and spatial learning performance in the Morris water maze in male and female meadow voles, Microtus pennsylvanicus. Horm Behav 1995;29:106-25.
-
(1995)
Horm Behav
, vol.29
, pp. 106-125
-
-
Galea, L.A.1
Kavaliers, M.2
Ossenkopp, K.P.3
Hampson, E.4
-
46
-
-
0028293411
-
Testosterone influences spatial cognition in older men
-
Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108:325-32.
-
(1994)
Behav Neurosci
, vol.108
, pp. 325-332
-
-
Janowsky, J.S.1
Oviatt, S.K.2
Orwoll, E.S.3
-
47
-
-
0035838329
-
Testosterone supplementation improves spatial and verbal memory in healthy older men
-
Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001;57:80-8.
-
(2001)
Neurology
, vol.57
, pp. 80-88
-
-
Cherrier, M.M.1
Asthana, S.2
Plymate, S.3
-
49
-
-
0642309499
-
Steroid hormones and cognitive functioning in aging men: A mini-review
-
Sherwin BB. Steroid hormones and cognitive functioning in aging men: a mini-review. J Mol Neurosci 2003;20:385-93.
-
(2003)
J Mol Neurosci
, vol.20
, pp. 385-393
-
-
Sherwin, B.B.1
-
50
-
-
34347215154
-
Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research
-
Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007;25:2455-63.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2455-2463
-
-
Vardy, J.1
Rourke, S.2
Tannock, I.F.3
-
51
-
-
41549111000
-
Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop
-
Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-9.
-
(2008)
Ann Oncol
, vol.19
, pp. 623-629
-
-
Vardy, J.1
Wefel, J.S.2
Ahles, T.3
Tannock, I.F.4
Schagen, S.B.5
-
52
-
-
78149480019
-
Impact of 12 months of androgen-deprivation therapy (adt) on cognitive function in men with nonmetastatic prostate cancer (pc): A matched cohort study [abstract 9027]
-
[Available online at, cited June 10, 2010]
-
Alibhai SMH, Marzouk S, Naglie G, et al. Impact of 12 months of androgen-deprivation therapy (adt) on cognitive function in men with nonmetastatic prostate cancer (pc): a matched cohort study [abstract 9027]. Proc Am Soc Clin Oncol 2010;28:7s. [Available online at: www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst_detail_view&confID= 74&abstractID=52729; cited June 10, 2010]
-
(2010)
Proc Am Soc Clin Oncol
, vol.28
-
-
Alibhai, S.M.H.1
Marzouk, S.2
Naglie, G.3
|